| Literature DB >> 30166322 |
Ane Arbillaga-Etxarri1,2,3,4, Elena Gimeno-Santos1,2,3,5,6, Anael Barberan-Garcia5,6, Eva Balcells2,7,8, Marta Benet1,2,3, Eulàlia Borrell9,10,11, Nuria Celorrio12, Anna Delgado1,2,3, Carme Jané13, Alicia Marin8,14, Carlos Martín-Cantera10,13,15, Mónica Monteagudo10,15, Nuria Montellà9,10,11, Laura Muñoz16, Pilar Ortega17, Diego A Rodríguez2,7,8, Robert Rodríguez-Roisin6, Pere Simonet10,18,19, Pere Torán-Monserrat10,11, Jaume Torrent-Pallicer1,2,3, Pere Vall-Casas20, Jordi Vilaró21, Judith Garcia-Aymerich1,2,3.
Abstract
There is a need to increase and maintain physical activity in patients with chronic obstructive pulmonary disease (COPD). We assessed 12-month efficacy and effectiveness of the Urban Training intervention on physical activity in COPD patients.This randomised controlled trial (NCT01897298) allocated 407 COPD patients from primary and hospital settings 1:1 to usual care (n=205) or Urban Training (n=202). Urban Training consisted of a baseline motivational interview, advice to walk on urban trails designed for COPD patients in outdoor public spaces and other optional components for feedback, motivation, information and support (pedometer, calendar, physical activity brochure, website, phone text messages, walking groups and a phone number). The primary outcome was 12-month change in steps·day-1 measured by accelerometer.Efficacy analysis (with per-protocol analysis set, n=233 classified as adherent to the assigned intervention) showed adjusted (95% CI) 12-month difference +957 (184-1731) steps·day-1 between Urban Training and usual care. Effectiveness analysis (with intention-to-treat analysis set, n=280 patients completing the study at 12 months including unwilling and self-reported non-adherent patients) showed no differences between groups. Leg muscle pain during walks was more frequently reported in Urban Training than usual care, without differences in any of the other adverse events.Urban Training, combining behavioural strategies with unsupervised outdoor walking, was efficacious in increasing physical activity after 12 months in COPD patients, with few safety concerns. However, it was ineffective in the full population including unwilling and self-reported non-adherent patients.Entities:
Mesh:
Year: 2018 PMID: 30166322 PMCID: PMC6203405 DOI: 10.1183/13993003.00063-2018
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671
FIGURE 1Study visits and assessments. COPD: chronic obstructive pulmonary disease.
FIGURE 2Components of the Urban Training intervention.
FIGURE 3Flow of participants through the trial. #: at baseline, three patients did not provide a valid record of physical activity due to technical reasons (e.g. patient entered the swimming pool and spoiled the record); ¶: reasons for exclusion between baseline and 12 months were spending >3 months per year away from their home address (n=7), mental disability (n=3), severe comorbidity limiting survival at 1 year (n=13) and another severe comorbidity (n=30); +: at the 12-month visit, six (2%) out of 286 patients did not fulfil the criterion of ≥3 days with ≥8 h of wearing time within waking hours.
Baseline characteristics of per-protocol and intention-to-treat analysis sets
| 145 | 88 | 233 | 148 | 132 | 280 | |
| 69±8 | 69±9 | 69±8 | 69±8 | 68±9 | 69±8 | |
| 17 (12)/128 (88) | 12 (14)/76 (86) | 29 (12)/204 (88) | 18 (12)/130 (88) | 18 (14)/114 (86) | 36 (13)/244 (87) | |
| 29 (20) | 20 (22) | 49 (21) | 30 (20) | 34 (26) | 64 (23) | |
| 105 (73) | 64 (73) | 169 (73) | 107 (73) | 93 (71) | 200 (72) | |
| 16 (12) | 13 (15) | 29 (13) | 16 (11) | 19 (15) | 35 (13) | |
| 1±1 | 1±1 | 1±1 | 1±1 | 1±1 | 1±1 | |
| 58±18 | 57±16 | 58±17 | 58±18 | 56±17 | 57±17 | |
| 0.55±0.12 | 0.54±0.10 | 0.54±0.12 | 0.55±0.12 | 0.53±0.11 | 0.54±0.12 | |
| 10/55/30/5 | 8/57/31/4 | 9/55/31/5 | 10/54/30/6 | 9/51/32/8 | 10/53/31/6 | |
| 37/44/7/12 | 35/52/0/13 | 36/47/4/13 | 36/44/7/13 | 31/53/3/13 | 34/48/5/13 | |
| 88 (61) | 52 (60) | 140 (60) | 90 (61) | 81 (62) | 171 (61) | |
| 37 (26) | 25 (29) | 62 (27) | 38 (26) | 44 (34) | 82 (29) | |
| 55 (38) | 30 (34) | 85 (37) | 56 (38) | 51 (39) | 107 (38) | |
| 2 (1–3) | 1 (1–2) | 2 (1–3) | 2 (1–3) | 2 (1–3) | 2 (1–3) | |
| 81 (57) | 47 (55) | 128 (56) | 82 (57) | 68 (53) | 150 (55) | |
| 113 (80) | 73 (86) | 186 (82) | 116 (80) | 109 (85) | 225 (82) | |
| 6 (4) | 5 (6) | 11 (5) | 6 (4) | 6 (5) | 12 (4) | |
| 6 (4) | 3 (3) | 9 (4) | 6 (4) | 6 (5) | 12 (4) | |
Data are presented as n, mean±sd, n (%) or median (interquartile range). ITT: intention-to-treat; mMRC: modified Medical Research Council; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; LAMA: long-acting muscarinic antagonist; LABA: long-acting β-agonist. #: some variables have missing values, as follows. Per-protocol analysis set: socioeconomic status (n=1) active worker (n=10), GOLD 2017 assessment (n=2), cardiovascular disease, diabetes and musculoskeletal disease (n=1), Charlson index (n=1) and inhaled corticosteroids and long-acting bronchodilators (n=6); ITT analysis set: socioeconomic status (n=2), active worker (n=11), GOLD 2017 assessment (n=3), cardiovascular disease, diabetes and musculoskeletal disease (n=1), Charlson index (n=1) and inhaled corticosteroids and long-acting bronchodilators (n=6); ¶: UK National Statistics Socio-economic Classification III, IV or V; +: chronic obstructive pulmonary disease severity mild (FEV1 ≥80% pred), moderate (FEV1 50–79% pred), severe FEV1 (30–49% pred), very severe (FEV1 <30% pred) and A (low risk, low symptom burden), B (low risk, high symptom burden), C (high risk, low symptom burden), D (high risk, high symptom burden); §: cardiovascular disease (International Classification of Diseases, 10th revision (ICD-10) I00–I99), diabetes mellitus (ICD-10 E10–E14), musculoskeletal diseases (ICD-10 M00–M99).
Effectiveness results (intention to treat analysis set) of Urban Training intervention at 12 months in chronic obstructive pulmonary disease (COPD) patients
| 148 | 132 | ||||
| Steps per day | 7783±3847 | 7825±3850 | 8069±4554 | 8002±4635 | −24 (−741–693) |
| Any severe COPD exacerbation in previous 12 months % | 14 | 17+ | 8 | 17+ | 0.3 (−0.4–1.0) |
| 6MWD m | 501±83 | 493±90+ | 499±95 | 488±106+ | −1.5 (−11–8) |
| BMI kg·m−2 | 28.3±4.6 | 28.3±4.5 | 28.4±5.0 | 28.5±5.2 | 0.0 (−0.3–0.4) |
| FFMI kg·m−2 | 19.6±3.2 | 19.5±3.0 | 19.6±3.0 | 19.6±3.1 | 0.1 (−0.4–0.5) |
| Health-related quality of life (CAT) | 12±8 | 11±7 | 12±7 | 11±7+ | 0.1 (−1.1–1.2) |
| Health-related quality of life (CCQ total) | 1±1 | 1±1 | 1±1 | 1±1+ | −0.1 (−0.3–0.1) |
| Anxiety (HAD-A) | 5±4 | 4±4+ | 5±4 | 5±4+ | 0.2 (−0.4–0.9) |
| Depression (HAD-D) | 3±3 | 3±3 | 4±3 | 3±3+ | −0.5 (−1.0–0.1) |
| Cognitive status (phototest) | 37±5 | 36±5 | 36±5 | 37±5 | 0.6 (−0.2–1.5) |
| Physical activity experience (C-PPAC total) | 79±12 | 77±12 | 78±12 | 80±14 | 2.6 (−0.8–6.0) |
| Physical activity experience of amount (C-PPAC amount) | 75±15 | 73±15 | 74±15 | 74±18 | 1.5 (−2.5–5.5) |
| Physical activity experience of difficulty (C-PPAC difficulty) | 83±13 | 81±14 | 82±15 | 85±15+ | 3.8 (−0.2–7.9) |
Data are presented as mean±sd, unless otherwise stated. 6MWD: 6-min walking distance; BMI: body mass index; FFMI: fat-free mass index; CAT: COPD Assessment Test; CCQ: Clinical COPD Questionnaire; HAD: Hospital Anxiety and Depression Scale; C-PPAC: Clinical visit – PROactive Physical Activity in COPD (higher numbers indicate a better score). #: some variables have missing values, as follows. At baseline in the usual-care group: severe COPD exacerbations (n=1), FFMI (n=18), HAD-A (n=2), HAD-D (n=2), C-PPAC total (n=25), C-PPAC amount (n=24) and C-PPAC difficulty (n=25); at 12 months in the usual-care group: severe COPD exacerbations (n=5), 6MWD (n=8), BMI (n=3), FFMI (n=3), CAT (n=2), CCQ total (n=2), HAD-A (n=2), HAD-D (n=2), cognitive status (n=2) and C-PPAC total, amount and difficulty scores (n=64); at baseline in Urban Training group: severe COPD exacerbations (n=2), FFMI (n=12), CCQ total (n=2), HAD-D (n=1) and C-PPAC total, C-PPAC amount and C-PPAC difficulty (n=35); at 12 months in Urban Training group: severe COPD exacerbations (n=5), 6MWD (n=3), BMI (n=2), FFMI (n=2), CAT (n=2), CCQ total (n=3), HAD-A (n=2), HAD-D (n=4), cognitive status (n=2) and C-PPAC total, amount and difficulty scores (n=70); ¶: multivariable models (linear regression for all outcomes except exacerbations where logistic regression was used) adjusted by group and the corresponding outcome values at baseline; + p-value of final versus baseline <0.05.
FIGURE 4a) Efficacy and b) effectiveness results of Urban Training intervention on steps per day (primary outcome) at 12 months in chronic obstructive pulmonary disease patients. Data are presented as mean±sem at baseline and 12 months.
Efficacy results (per-protocol analysis set) of Urban Training intervention at 12 months in chronic obstructive pulmonary disease (COPD) patients
| 145 | 88 | ||||
| Steps per day | 7846±3845 | 7911±3830 | 8355±4177 | 9171±4704+ | 957 (184–1731)§ |
| Any severe COPD exacerbation in previous 12 months % | 14 | 16+ | 5 | 15+ | 0.15 (−0.7–1) |
| 6MWD m | 503±79 | 496±86+ | 509±83 | 502±97 | 3.6 (−6.9–14.2) |
| BMI kg·m−2 | 28.2±4.5 | 28.2±4.5 | 28.3±4.5 | 28.5±4.5 | 0.2 (−0.2–0.5) |
| FFMI kg·m−2 | 19.6±3.2 | 19.5±3.0 | 19.5±2.8 | 19.5±2.8 | 0.1 (−0.4–0.6) |
| Health-related quality of life CAT | 12±8 | 11±7+ | 12±7 | 10±7+ | −0.7 (−2.1–0.6) |
| Health-related quality of life CCQ total | 1±1 | 1±1 | 1±1 | 1±1 | −0.1 (−0.3–0.1) |
| Anxiety HAD-A | 5±4 | 4±4+ | 5±4 | 5±4 | 0.2 (−0.5–0.9) |
| Depression HAD-D | 3±3 | 3±3 | 3±3 | 2±3+ | −0.5 (−1.1–0.1) |
| Cognitive status (phototest) | 37±5 | 36±5 | 36±5 | 36±6 | 0.5 (−0.4–1.5) |
| Physical activity experience (C-PPAC total score) | 79±12 | 78±11 | 79±11 | 84±11+ | 5.2 (1.3–9.2)+ |
| Physical activity experience of amount (C-PPAC amount) | 75±15 | 74±14 | 76±12 | 80±13+ | 5.7 (1.1–10.2)+ |
| Physical activity experience of difficulty (C-PPAC difficulty) | 83±13 | 81±13 | 83±16 | 88±14+ | 5.0 (0.3–9.6)+ |
Data are presented as n, mean±sd or adjusted difference (95% CI). 6MWD: 6-min walking distance; BMI: body mass index; FFMI: fat-free mass index; CAT: COPD Assessment Test; CCQ: Clinical COPD Questionnaire; HAD: Hospital Anxiety and Depression Scale; C-PPAC: Clinical visit – PROactive Physical Activity in COPD (higher numbers indicate a better score). #: some variables have missing values, as follows. At baseline in the usual-care group: severe COPD exacerbations (n=1), FFMI (n=18), HAD-A (n=2), HAD-D (n=2), C-PPAC total (n=24), C-PPAC amount (n=23) and C-PPAC difficulty (n=24); at 12 months in the usual-care group: severe COPD exacerbations (n=5), 6MWD (n=7), BMI (n=2), FFMI (n=2), CAT (n=1), CCQ total (n=1), HAD-A (n=1), HAD-D (n=1), cognitive status (n=1) and C-PPAC total, amount and difficulty scores (n=63); at baseline in Urban Training group: severe COPD exacerbations (n=1), FFMI (n=5), HAD-D (n=1) and C-PPAC total, amount and difficulty scores (n=24); at 12 months in Urban Training group: severe COPD exacerbations (n=2), 6MWD (n=1), CCQ total (n=1), HAD-D (n=1) and C-PPAC total, amount and difficulty scores (n=47); ¶: multivariable models (linear regression for all outcomes except exacerbations where logistic regression was used) adjusted by group, forced expiratory volume in 1 s/forced vital capacity ratio, smoking, diabetes, HAD-depression score (online supplementary material) and the corresponding outcome values at baseline; +: p-value of final versus baseline <0.05; §: p-value for group differences <0.05.
FIGURE 5Efficacy of Urban Training intervention on steps per day (primary outcome) at 12 months in chronic obstructive pulmonary disease (COPD) patients according to subgroups based on baseline characteristics. Data are presented as adjusted difference (95% CI) at 12 months between intervention and usual-care groups. Subgroups defined by baseline airflow limitation stages (mild to moderate versus severe to very severe), functional exercise capacity (median 6-min walking distance (6MWD) <500 versus ≥500 m), comorbidity (Charlson index <2 versus ≥2) and physical activity levels (baseline <7100 versus ≥7100 steps per day, cut-off equivalent to being adherent to physical activity recommendations for older adults) [30].
Adverse events during or after walks in the safety analysis set
| 142 | 128 | ||
| 103 (73) | 99 (77) | 0.363 | |
| 38 (27) | 41 (32) | 0.342 | |
| 36 (25) | 48 (38) | 0.031 | |
| 61 (43) | 57 (45) | 0.795 | |
| 12 (8) | 9 (7) | 0.821 | |
| 1 (1) | 0 (0) | ||
| 48 (34) | 46 (36) | 0.713 | |
| 9 (6) | 17 (13) | 0.064 | |
| 22 (16) | 23 (18) | 0.586 | |
| 10 (7) | 13 (10) | 0.360 | |
| 24 (17) | 21 (16) | 0.913 | |
| 1 (1) | 2 (2) | 0.605 |
Data are presented as n (%), unless otherwise stated.